Compare Carnival Corp (CCL) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Carnival Corp vs State Street SPDR S&P Biotech ETF — how do they compare? Carnival Corp trades at $27.76 (market cap $37.98B), while State Street SPDR S&P Biotech ETF trades at $159.64. The key difference: Carnival Corp pays a 1.62% dividend while State Street SPDR S&P Biotech ETF pays none, and State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, Carnival Corp nearer its low. Which is the better fit depends on your goals.
| CCL | XBI | |
|---|---|---|
Market Cap | $37.98B | — |
Sector | Consumer Cyclical | Broad Market / Factor |
52-Week High | $33.99 | $164.28 |
52-Week Low | $23.89 | $86.92 |
Enterprise Value | $61.91B | — |
Dividend Yield | 1.62% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Carnival Corporation (CCL) trades at $27.75, down 4.28% today, amid a bearish technical signal. The company shows strong fundamental recovery with revenue growing from $12.2B in 2022 to $26.6B in 2025, net income turning positive to $2.76B, and positive cash flow of $727M in 2025. Recent earnings beats and a 59.57% analyst buy rating support optimism, though technical indicators show near-term pressure with support at $27.
Outlook remains positive driven by record travel demand, fleet expansion, and debt reduction, with a consensus price target of $35.18 offering 27% upside. Key risks include fuel price volatility, economic sensitivity, and execution of growth plans amid competitive pressures.
XBI trades at $159.15, up 0.71% with a bullish technical signal from moving averages. The biotech ETF shows strong momentum with a 17% monthly gain, driven by positive clinical data and M&A activity. Analyst coverage remains limited with a single hold rating, while institutional interest grows with recent $793,000 investment from Bay Colony Advisors.
Outlook remains positive given biotech sector resurgence, though elevated RSI suggests near-term overbought conditions. Key risks include sector volatility and regulatory uncertainty, but AI-driven drug discovery and strong pipeline developments provide growth catalysts for patient investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Carnival Corp
Carnival is the largest global cruise company, with 91 ships in its fleet in October 2022, with eight of its nine brands set to be fully redeployed by the end of 2022. Its portfolio of brands includes Carnival Cruise Lines, Holland America, Princess Cruises, and Seabourn in North America.
Read more on CCL →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
